Safety Study of Denosumab in Subjects With Recurrent or Unresectable Giant Cell Tumor of Bone
Safety Study of Denosumab in Subjects With Recurrent or Unresectable Giant Cell Tumor of BoneSponsors and Collaborators
Amgen
Contact
Amgen Call Center
866-572-6436
Investigator
Amgen
ClinicalTrials.gov Identifier
NCT00680992